Amnesia and palimpsests occurring and recurring in alcohol addicts due to alcohol intoxication (Ebrietas alcoholica) are accompanied by hazardous memory failures, gradual mental degradation and psychoorganic syndrome, which evidences urgent clinical, therapeutic and therapeutic issue in addictology, psychiatry, forensic medicine, sociology, medical psychology, etc. At EPA initiative (2019), research interest in non-invasive brain stimulation tools and methods for such populations was activated.

Development of a patentable method of treatment in addictology using pyracetam and nicotinic acid transcerebral electrophoresis (TCE).

Valid clinical-diagnostic, laboratory, biochemical, electrophysiological, psychological (scaling, testing), statistical methods for identification of alcohol dependence complicated by amnestic disorders.

The method of treatment of alcohol dependence complicated by amnestic disorders (Patent 141785 UA) provides complex pharmacological and drug-free therapy. Antiamnesic drugs are administered by TCE bilaterally; pyracetam 20% solution to the left orbit through active negative electrodes, and nicotinic acid 0.1% solution to the right orbit (positive electrode in the occipital fossa), current of 2-4 mA, 20-30 minutes exposure. The procedure was performed daily with a TCE device, for a 10-day course of treatment along with psychotherapeutic potentiation. TCE provides the ionic implementation of pharmacological agents in the brain and their physiological electrical stimulation.

In a representative clinical trial, using statistical methods and generated bank of patient-specific observations, significant potentiating effects of combined drug-free, non-invasive transcerebral electrical stimulation and electrophoretic implementation of pyracetam and nicotinic acid were demonstrated.

Currently, alcohol dependence is characterized by immediate onset of dipsomania states (code F10.26, ICD-10) interpreted in clinical addictology as reliable diagnostic signs of morbid alcohol dependence. These are classified clinically by rate, severity, therapeutically resistant post alcohol comorbidities (alcohol-induced polyneuropathy, hepatic dysfunctions, etc.), and by the presence of “lucid spaces”, when patients, depleted physically and mentally by hypertoxic alcohol abuse states, periodically (after binge drinking) intake no alcohol.

Effectiveness improvement and reducing time of treatment for hypertoxic alcohol abuse states by reasonable pathogenetic use of highly effective drugs, wide polymodality and synergistic pharmacological range, with few side effects, potential for inclusion to the conventional standard treatment patterns according to thiamine concepts.

Valid clinical-diagnostic, laboratory, biochemical, electrophysiological, psychological (scaling, testing), statistical methods for identification of alcohol dependence complicated by hypertoxic alcohol abuse states.

A new method of alleviating the hypertoxic intoxication in alcohol dependence has been developed on representative clinical material, which involves conventional pharmacological and drug-free symptomatic remedies and methods. Along with psychotherapeutic potentiation, a therapeutically targeted pharmacological complex was prescribed: intramuscular Vitaxon № 10 per course; Sibazon 0.5% solution, 2 ml intramuscular, 3-5 injections per course; oral Phenazepam, one tablet (0.001g) twice a day for 10-14 days; Cocarnit one ampoule daily intramuscular injection, for a course of 3-10 injections.

The effectiveness of the proposed pharmacological complex has been proven by the statistical reliability method and illustrated by clinical examples of patient-specific research.

Age-related features of alcohol addiction in elderly women (AAEW) have not been studied properly. The WHO classifies 60-75 years as elderly age (‘early old age’), when morphological and physiological functions of all organs and systems fade away, causing severe post-intoxication and withdrawal disorders, giving organic tint to alcohol dependence clinical picture, and rapid onset of alcoholic mental degradation of personality.

To study specific clinical, diagnostic and pathophysiological basis of alcohol dependence in aged women for innovative approaches to AAEW treatment.

Clinical and medical history questioning, international tests and scales to identify alcohol dependence and complications in elderly women. Follow-up monitoring of basic biochemical, clinical, laboratory and electrophysiological findings at treatment runtime.

Multifactorial study and specific gender features in AAEW development allowed to identify abundant dual comorbidity, prevalence, high degree of affective disorders (depression, anxiety, dysphoria) combined with various somatic conditions and diencephalic symptoms in this alcoholic disease pattern. New treatment modality for alcohol dependence in elderly women was proposed and tested; along with classical detoxification and symptomatic therapy, the patients received anxiolytic agent (serotonin receptor stimulator) Buspirone SANDOZ, 5 mg 3 times a day, followed by individually corrected effective dose. The drug stopped anxiety, balanced the mood, causing no addiction. Buspirone was combined with bromine and sodium sulfate transcerebral electrophoresis № 5 and selective psychotherapy.

The proposed integrated therapy for AAEW was proven to be effective by statistical reliability and patient-specific clinical illustrations.

Alcohol amnesia and palimpsests belong to understudied areas in addictology concerning the pathogenesis, risk factors, and development of effective integrated, targeted modalities of therapy, prevention, and after-treatment care.

Development of a new integrated, pathogenetically grounded approach to the emergency and routine therapy for immediate and long-term consequences of amnestic alcohol intoxication.

Modern complex clinical-psychopathological, pathopsychological, laboratory, electrophysiological, biochemical examination; method of analogues and prototype analytical examination.

Integrated anti-amnestic pharmacotherapeutic triad: Noobut IC (Phenibut) orally, before meals, for 6 days, twice a day: 250 mg in the morning, 500 mg at night, within days 7-14 250 mg twice: in the morning and at night; Vitaxon 2.0 ml daily, intramuscularly, No10 totally; ozone therapy for 10 days (ozone dissolved in olive oil, 6 mg/100 ml concentration), 5 ml orally 3 times a day. Complex therapy is concurrent with synergistic psychotherapeutic potentiation. Supportive anti-relapse prevention of alcohol-induced amnesia, palimpsests with Noobut IC: 1 tablet (250 mg) orally in the morning for 2 months. The pathogenetic support of the pharmacotherapeutic triad in treatment for alcohol addiction, comorbid with amnestic disorders, is pathogenetically focused on pharmacological properties of each component of the triad and their potentiating effects, involving most pathogenetic mechanisms of this disease.

Relieving and prophylactic efficacy of the proposed pharmacological triad (Noobut, Vitaxon, ozone and concurrent psychotherapeutic potentiation) is proven by the statistical reliability method and illustrated by clinical examples of patient-specific research.